BioCentury
ARTICLE | Clinical News

No safety signals with Zafgen's ZGN-1061 in second cohort of diabetes trial

January 18, 2019 8:27 PM UTC

Zafgen Inc. (NASDAQ:ZFGN) said the 1.8 mg subcutaneous dose of ZGN-1061 met primary and secondary endpoints in a second dose cohort from a Phase II trial to treat Type II diabetes. The adverse event profile of 1.8 mg ZGN-1061 was comparable to placebo.

The 1.8 mg dose of ZGN-1061 reduced HbA1c by 1.1% from baseline at week 12 vs. placebo (p<0.0001), meeting the primary endpoint. The dose also met the secondary endpoint of reducing body weight vs. placebo (p=0.0002), and produced substantially greater improvement in HbA1c levels than the 0.9 mg dose. The second cohort from the trial enrolled 40 patients who received 0.9 or 1.8 mg subcutaneous doses of ZGN-1061 every three days for 12 weeks...

BCIQ Company Profiles

Zafgen Inc.